Compass Therapeutics is a Boston biopharmaceutical company developing antibody drugs to treat cancer. It last closed at $0.61 on Nov 17, down 8.28% on the day. The average 12-month price target from 5 analysts is $5.78 (+852.7% from the last close), with a high of $12.00 and a low of $0.90. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (4 buy, 1 hold, 0 sell).
Each firm's latest rating on CMPX in the past 90 days
Average 12-month target
$5.78
▲ 852.7% upside
Based on 5 analysts who set a price target on CMPX in the past 90 days. The average target is $5.78, with a high of $12.00 and a low of $0.90, compared with the last close of $0.61.
Low $0.90Avg $5.78High $12.00
Blue marker: last close $0.61
Highest target$12.00
Average target$5.78
Lowest target$0.90
Latest rating changes
WedbushTarget lowered
Nov 10Hold$1 → $0.90
Craig-HallumMaintained
Sep 23Buy$8
CitizensMaintained
Sep 23Buy$4
GuggenheimMaintained
Sep 23Buy$4
WedbushDowngrade
Sep 23Hold$1
Date
Firm
Action
Rating
Price target
Nov 10
Wedbush
Target lowered
Hold
$1 → $0.90
Sep 23
Craig-Hallum
Maintained
Buy
$8
Sep 23
Citizens
Maintained
Buy
$4
Sep 23
Guggenheim
Maintained
Buy
$4
Sep 23
Wedbush
Downgrade
Hold
$1
Loading…
Technical Analysis
CMPX · as of the Nov 17 close · updated after every close
Downtrend, oversold
The stock is 26% below its 20 day and 76% below its 50 day average. It is 373% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $0.57, and the nearest resistance the Pivot at $0.61.
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 12.1%/day
Key levels
$6.8852 week high+1027.9%
$2.87200 day average+370.5%
$1.64100 day average+168.9%
$1.0750 day average+75.4%
$0.81Swing high (Nov 2)+32.8%
$0.7620 day average+24.6%
$0.65Pivot R1+6.6%
$0.61Pivot+0.0%
$0.61Last close
$0.5752 week low−6.6%
$0.56Pivot S1−8.2%
Indicators
RSI (14)
27.01
Oversold below 30
Oversold
MACD
-0.10
Above its signal line
Bullish
Stochastic
19.2
Near the bottom of its range
Oversold
ADX (14)
45.8
Strong downtrend
Williams %R
-88.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-286.4
Oversold below −100, overbought above 100
Oversold
Rate of change
−20.7%
Change over 10 sessions
Bearish
ATR (14)
$0.07
Typical daily range, 12.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 53.8%/day
Key levels
$6.8852 week high+1027.9%
$2.87200 day average+370.5%
$1.64100 day average+168.9%
$1.0750 day average+75.4%
$0.81Swing high (Nov 2)+32.8%
$0.7620 day average+24.6%
$0.65Pivot R1+6.6%
$0.61Pivot+0.0%
$0.61Last close
$0.5752 week low−6.6%
$0.56Pivot S1−8.2%
Indicators
RSI (14)
25.82
Oversold below 30
Oversold
MACD
-0.67
Below its signal line
Bearish
Stochastic
4.0
Near the bottom of its range
Oversold
ADX (14)
34.7
Trending down
Williams %R
-98.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-98.5
Oversold below −100, overbought above 100
Neutral
Rate of change
−69.7%
Change over 10 sessions
Bearish
ATR (14)
$0.33
Typical daily range, 53.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CMPX
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how CMPX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow CMPX usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CMPX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CMPX is in one of them and how their past CMPX trades turned out.
Compass Therapeutics is a biopharmaceutical company based in Boston, Massachusetts, that develops antibody drugs for cancer. Its lead candidate, tovecimig, is designed to block two signaling pathways that tumors use to grow new blood vessels, and it is being tested in patients with biliary tract cancer. The company also has three other clinical stage candidates that target immune system pathways, including CD137 and PD-1. None of these candidates has been approved for sale.